Bank of Montreal
SYRS

Bank of Montreal’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Bank of Montreal’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-153
Closed -$11K – 5052
2021
Q1 		$11K Sell
153
-555
-78% -$57.7K ﹤0.01% 4348
2020
Q4 		$85K Buy
708
+515
+267% +$47K ﹤0.01% 3678
2020
Q3 		$17K Sell
193
-140
-42% -$15.9K ﹤0.01% 3910
2020
Q2 		$40K Buy
+333
New +$29.9K ﹤0.01% 3535
2020
Q1 		– Sell
-440
Closed -$30K – 4820
2019
Q4 		$30K Buy
440
+136
+45% +$8.25K ﹤0.01% 4088
2019
Q3 		$32K Buy
304
+7
+2% +$661 ﹤0.01% 3836
2019
Q2 		$27K Buy
297
+294
+9,800% +$20.5K ﹤0.01% 4018
2019
Q1 		$0 Sell
3
-34
-92% -$2.37K ﹤0.01% 4824
2018
Q4 		$2K Buy
37
+19
+106% +$1.44K ﹤0.01% 4436
2018
Q3 		$2K Buy
18
+1
+6% +$116 ﹤0.01% 4412
2018
Q2 		$2K Buy
+17
New +$2.1K ﹤0.01% 4417

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bank of Montreal's SYRS Position: Q2 2021 in Review

Bank of Montreal sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2021, closing a stake of 153 shares — an estimated $11K sold.

Bank of Montreal first reported a position in SYRS in Q2 2018 and held it in 11 quarters. The position peaked at $85K in Q4 2020. 100 funds tracked by Wall St. Rank hold SYRS as of Q2 2021.

  • Bank of Montreal reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Bank of Montreal sold 153 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $11K.
  • Bank of Montreal first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 11 quarters.
  • Bank of Montreal's Syros Pharmaceuticals, Inc. Common Stock position peaked at $85K in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Bank of Montreal's 13F filing for Q2 2021, filed 12 Aug 2021.